VU6007477 manufacturers
- VU6007477
-
- $2780.00
-
2026-04-21
- CAS:2220141-46-6
- Purity: 99.67%
- Supply Ability: 10g
|
| | VU6007477 Basic information |
| Product Name: | VU6007477 | | Synonyms: | VU6007477;1H-Pyrrolo[2,3-b]pyridine-6-carboxamide, 1-methyl-4-[[6-(1-methyl-1H-pyrazol-4-yl)-3-pyridinyl]methyl]-N-(tetrahydro-2H-pyran-4-yl)- | | CAS: | 2220141-46-6 | | MF: | C24H26N6O2 | | MW: | 430.5 | | EINECS: | | | Product Categories: | | | Mol File: | 2220141-46-6.mol |  |
| | VU6007477 Chemical Properties |
| Boiling point | 711.3±60.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | pka | 12.07±0.20(Predicted) |
| | VU6007477 Usage And Synthesis |
| Description | VU6007477 is a novel M1 PAM. VU6007477 resulted in good rat M1 PAM potency (EC50 = 230 nM, 93% ACh max), minimal M1 agonist activity (agonist EC50 > 10 μM), good CNS penetration (rat braiplasma Kp = 0.28, Kp,uu = 0.32; mouse Kp = 0.16, Kp,uu = 0.18), and no cholinergic adverse events (AEs, e.g., seizures). | | Uses | VU6007477 is a brain-penetrant, selective M1 positive allosteric modulator (PAM) with an EC50 value of 230 nM. VU6007477 is also a human P-glycoprotein (P-gp) substrate with moderate permeability. VU6007477 displays improved central nervous system (CNS) penetration over the hydroxylated congeners. VU6007477 a pyranyl amide derivative, which is promising for research of robust cholinergic seizure activity[1]. | | References | [1] Engers JL, et al. VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. ACS Med Chem Lett. 2018 Sep 4;9(9):917-922. DOI:10.1021/acsmedchemlett.8b00261 |
| | VU6007477 Preparation Products And Raw materials |
|